Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J Clin Oncol, vol.28, pp.2144-50, 2010. ,
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.27, pp.3584-90, 2009. ,
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, Lancet Oncol, vol.14, pp.552-62, 2013. ,
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study, J Clin Oncol, vol.32, pp.1412-1420, 2014. ,
Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N Engl J Med, vol.369, pp.722-753, 2013. ,
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1814-1837, 2015. ,
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors, Cancer, vol.116, pp.4256-65, 2010. ,
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, pp.883-92, 2012. ,
A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth, Blood, vol.102, pp.184-91, 2003. ,
Prognostic value of CD146 in solid tumor: A Systematic Review and Meta-analysis, Sci Rep, vol.7, p.4223, 2017. ,
CD146, a multi-functional molecule beyond adhesion, Cancer Lett, vol.330, pp.150-62, 2013. ,
Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146, Biochim Biophys Acta, vol.1795, pp.130-136, 2009. ,
Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer, Prostate, vol.68, pp.418-444, 2008. ,
CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis, Blood, vol.120, pp.2330-2339, 2012. ,
CD146: a new partner for VEGFR2, Blood, vol.120, pp.2164-2169, 2012. ,
Soluble CD146 boosts therapeutic effect of endothelial progenitors through proteolytic processing of short CD146 isoform, Cardiovasc Res, vol.111, pp.240-51, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01456844
Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process, Microvasc Res, vol.78, pp.325-356, 2009. ,
Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors, Oncogene, vol.35, pp.5489-500, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01456904
Angiomotin Family Members: Oncogenes or Tumor Suppressors?, Int J Biol Sci, vol.13, pp.772-81, 2017. ,
Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation, J Cell Biol, vol.152, pp.1247-54, 2001. ,
Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases, Proc Natl Acad Sci U S A, vol.110, pp.17368-73, 2013. ,
Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer, Br J Cancer, vol.110, pp.1236-1279, 2014. ,
Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype, Clin Genitourin Cancer, vol.15, pp.1-7, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01470708
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas, Cancer Res, vol.77, pp.1212-1238, 2017. ,
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial, Lancet Oncol, vol.12, pp.673-80, 2011. ,
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux, Autophagy, vol.11, pp.1891-904, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02108861
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma, PLoS ONE, vol.9, p.89449, 2014. ,
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, vol.6, p.1, 2013. ,
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, vol.2, pp.401-405, 2012. ,
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma, Br J Cancer, vol.113, pp.12-21, 2015. ,
CD146 and its soluble form regulate monocyte transendothelial migration, Arterioscler Thromb Vasc Biol, vol.29, pp.746-53, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00428932
CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer, Int J Mol Sci, vol.13, pp.6399-406, 2012. ,
CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition, PLoS One, vol.7, p.43752, 2012. ,